Autoimmune hepatitis: Focusing on treatments other than steroids

Albert J Czaja MD


BACKGROUND: Corticosteroid therapy has been the time-honoured treatment for autoimmune hepatitis; however, the emergence of new immunosuppressive agents has afforded opportunities to improve or replace the standard regimens.

OBJECTIVE: To describe technological advances and feasible treatment interventions that promise to supplant the current generation of corticosteroids.

METHODS: A review of the MEDLINE database for published experiences from 1984 to 2011 was conducted.

RESULTS: Cyclosporine and tacrolimus have been uniformly successful as salvage therapies for steroid-refractory autoimmune hepatitis. Ten reports of cyclosporine therapy involving 133 patients had positive outcomes in 93%, whereas therapy with tacrolimus in three reports involving 41 patients had positive outcomes in 98%. Salvage therapy with mycophenolate mofetil had a favourable outcome in 47%, especially in patients with azathioprine intolerance. Front-line therapy with mycophenolate mofetil normalized liver parameters in 88% and allowed corticosteroid tapering in 58%. Front-line therapy with budesonide combined with azathioprine for six months normalized liver parameters more frequently (47% versus 18%) and with fewer side effects (28% versus 53%) than prednisone combined with azathioprine. Monoclonal antibodies to CD3 and recombinant cytotoxic T lymphocyte antigen 4 fused with immunoglobulin represent feasible molecular interventions for study in autoimmune hepatitis.

DISCUSSION: Nonstandard drug therapies must be used in highly selected clinical situations including steroid failure (calcineurin inhibitors), azathioprine intolerance (mycophenolate mofetil), and mild disease or fragile patients (budesonide combined with azathioprine). Molecular interventions for autoimmune hepatitis are feasible for study because of their use in other immune-mediated diseases.

CONCLUSION: Opportunities to improve or replace standard corticosteroid regimens have emerged.

Key Words: Autoimmune; Front-line; Hepatitis; Molecular; Salvage; Therapy

L’hépatite auto-immune : cibler d’autres traitements que les stéroïdes

HISTORIQUE : La corticothérapie est le traitement immuable de l’hépatite auto-immune. Cependant, l’émergence de nouveaux immunosuppresseurs donne l’occasion d’améliorer ou de remplacer les médicaments habituels.

OBJECTIF : Décrire les progrès technologiques et les interventions thérapeutiques possibles qui promettent de supplanter la génération actuelle de corticoïdes.

MÉTHODOLOGIE : Les chercheurs ont procédé à une analyse de la base de données MEDLINE afin d’extraire les expériences publiées entre 1984 et 2011.

RÉSULTATS : La cyclosporine et le tacrolimus ont toujours été efficaces comme thérapies de rattrapage de l’hépatite auto-immune réfractaire aux stéroïdes. Sept rapports de traitements à la cyclosporine auprès de 33 patients ont fait foi d’une issue positive dans 82 % des cas, tandis que trois rapports au sujet de 41 patients subissant un traitement au tacrolimus ont souligné une issue positive dans 98 % des cas. La thérapie de rattrapage au moïlyphénolate a eu une issue positive dans 47 % des cas, notamment chez des patients intolérants à l’azathioprine. La thérapie de première ligne au moïlyphénolate normalise les paramètres hépatiques dans 88 % des cas et permet de réduire graduellement la corticothérapie dans 58 % des cas. La thérapie de première ligne au budesonide associée à l’azathioprine administrée pendant six mois a normalisé les paramètres hépatiques plus fréquemment (47 % par rapport à 18 %) et causé moins d’effets secondaires (28 % par rapport à 53 %) que la prednisone combinée à l’azathioprine. Les anticorps monoclonaux anti-CD3 et l’antigène 4 du lymphocyte T cytotoxique recombinant fusionnés avec l’immunoglobuline représentent des interventions moléculaires possibles en vue d’études sur l’hépatite auto-immune.

EXPOSÉ : Il faut utiliser les médicaments habituels non standard dans des situations cliniques extrêmement bien sélectionnées, y compris l’échec des stéroïdes (inhibiteurs de la calcineurine), l’intolérance à l’azathioprine (moïlyphénolate) et une maladie bénigne ou des patients fragiles (budesonide associée à l’azathioprine). Il est possible d’étudier des interventions moléculaires pour le traitement de l’hépatite auto-immune en raison de leur utilisation dans d’autres maladies à médiation immunitaire.

CONCLUSION : Des possibilités d’améliorer ou de remplacer la corticothérapie standard ont vu le jour.
cycles are stalled; and lymphocyte proliferation is blunted of interleukin (IL)-2. Activation of the IL-2 receptor (IL-2R) is impaired; cell block calcineurin-mediated activation of nuclear factor-kappa B (NF-κB) and stimulates lymphocyte proliferation. Cyclosporine and tacrolimus each...titis since 1995 (27). The starting dose of tacrolimus in the various... have each been used in autoimmune hepatitis patients, primarily as sal-

Figure 1) Mechanisms of action of calcineurin inhibitors within lymphocytes. Lymphocyte activation requires recognition of the antigen (Ag) presented by the class II molecule of the major histocompatibility complex (MHC) on the surface of the antigen presenting cell (APC) by the T cell antigen receptor (TCR) of the lymphocyte (Signal 1). Binding of the B7 ligands on the surface of the APC to CD28 molecules on the surface of the lymphocyte completes the second costimulatory signal (signal 2) and activates the lymphocyte. Lymphocyte activation releases calcium (Ca²⁺), which activates calcineurin and stimulates lymphocyte proliferation. Cyclosporine and tacrolimus each...phosphatase activity, interfere with the proliferation of lymphocytes and blunt cell-mediated immune responses. Cyclosporine and tacrolimus have each been used in autoimmune hepatitis patients, primarily as salv-

molecular interventions include monoclonal antibodies that interfere with the immune response and recombinant molecules that favourably modulate the cytokine pathways responsible for lymphocyte differen-

Calcineurin Inhibitors
Calcineurin activates nuclear factor-κB via a pathway dependent on phosphatase activity (Figure 1) (19). The activated nuclear factor binds to promoter regions of the interleukin (IL)-2 gene and increases tran-
scription of IL-2. In turn, IL-2 stimulates the cell cycle by binding to the IL-2 receptor, and lymphocytes proliferate along a type 1 cytokine path-
way. Cyclosporine and tacrolimus are calcineurin inhibitors that impair phosphatase activity, interfere with the proliferation of lymphocytes and blunt cell-mediated immune responses. Cyclosporine and tacrolimus have each been used in autoimmune hepatitis patients, primarily as sal-

Cyclosporine
Cyclosporine has been used as a salvage therapy for autoimmune hepatitis since 1985 (20). Ten reports involving 133 patients over the past 26 years (20-26) indicated that a positive response of any degree was achieved in 93%, and a negative response, defined as no response or drug intolerance, was reported in 7% (Table 1). In the most recent experience involving 19 patients treated for 26 weeks with cyclo-

Tacrolimus
Tacrolimus has been used as a salvage therapy for autoimmune hepato-

Mycophenolate Mofetil
Mycophenolate mofetil is a next-generation purine antagonist that has been used as a front-line drug and as a salvage agent for autoimmune hepatitis (15,17). It is a prodrug that is hydrolyzed by liver esterases to mycophenolic acid, which in turn acts as a reversible noncompetitive inhibitor of inosine monophosphate dehydrogenase (30) (Figure 2). Mycophenolate mofetil can thereby selectively impair the synthesis of purine-based nucleotides, inhibit the creation of new DNA and impair the proliferation of activated lymphocytes. Its activation and elimination are independent of the thiopurine methyltransferase pathway. Eleven small single-centre experiences have indicated that myco-

Side Effects
The success of the calcineurin inhibitors as a salvage therapy for autoimmune hepatitis has been impressive, but the overall reported clinical experience with these agents has been lacking. Calcineurin inhibitors still lack a uniform dosing schedule, an acceptable safety profile and an established monitoring protocol for autoimmune hepato-

Tacrolimus has been used as a salvage therapy for autoimmune hepato-

The success of the calcineurin inhibitors as a salvage therapy for autoimmune hepatitis has been impressive, but the overall reported clinical experience with these agents has been lacking. Calcineurin inhibitors still lack a uniform dosing schedule, an acceptable safety profile and an established monitoring protocol for autoimmune hepato-

Can J Gastroenterol Vol 26 No 9 September 2012
management strategy when using mycophenolate mofetil off label. Mycophenolate mofetil is six to seven times more expensive than azathioprine (43,44); treatment ending side effects occur in 3% to 13% (41,42); most patients require continuous corticosteroid therapy; the duration of treatment is indefinite; and the drug is more effective in rescuing patients with azathioprine intolerance than steroid-refractory liver disease (37,40,41). Mycophenolate mofetil has a limited and evolving role in autoimmune hepatitis, and its use as a salvage therapy for azathioprine intolerance is currently its most effective application (45).

BUDESONIDE

Budesonide is a next-generation glucocorticoid that has >90% first-pass clearance in the liver, with metabolites devoid of glucocorticoid activity (46) (Table 1). Its steroidal nature does not disqualify its consideration in the present review because budesonide promises to move current therapies away from reliance on prednisone or prednisolone. Furthermore, budesonide is the first drug in autoimmune hepatitis to be assessed in a large randomized clinical trial in more than 40 years (47). In this regard, it has legitimized its place in the treatment algorithm to a greater degree than the true alternatives to traditional steroids.

Budesonide was first used in the treatment of autoimmune hepatitis in 1994 (48) and, over the past 17 years, six studies involving 162 patients, 100 of whom were enrolled in a randomized clinical trial (47), have helped define its role in autoimmune hepatitis (47-52) (Table 1). Early experiences indicated difficulties in using this drug as a salvage agent in prednisone-dependent patients (49). Attempts to switch from prednisone to budesonide were complicated by severe withdrawal arthralgias and typical corticosteroid-induced side effects (49). Altered hepatic metabolism in patients with cirrhosis was associated with the development of serious drug-related complications (53); immune-mediated diseases concurrent with autoimmune hepatitis could exacerbate (49); and flares of autoimmune hepatitis during therapy were always possible (54). These experiences characterized the ideal target population for the drug and directed its use toward treatment-naive, noncirrhotic and uncomplicated patients.

TABLE 1
Alternative drugs to prednisone for autoimmune hepatitis

<table>
<thead>
<tr>
<th>Drug, dose (reference[s])</th>
<th>Mechanism of action (reference[s])</th>
<th>Clinical indication (reference[s])</th>
<th>Outcomes (reference[s])</th>
</tr>
</thead>
</table>
| Cytosporine, 2 mg/kg/day to 5 mg/kg/day (26) | Calcineurin inhibitor (19) | Steroid-failure (20-26) | Composite results (20-26):  
- Improvement, 93%  
- Failure/side effects, 7% |
|                          | Impairs FKBP (19)                |                                  |                        |
|                          | Reduces IL-2 (19)                |                                  |                        |
|                          | Impairs lymphocyte proliferation (19) |                                  |                        |
| Tacrolimus, 0.5 mg/day to 3 mg twice/day (27-29) | Calcineurin inhibitor (19) | Steroid-failure (27-29) | Composite results (27-29):  
- Improvement, 98%  
- Failure/side effects, 2% |
|                          | Impairs FKBP (19)                |                                  |                        |
|                          | Reduces IL-2 (19)                |                                  |                        |
|                          | Impairs lymphocyte proliferation (19) |                                  |                        |
| Mycophenolate mofetil, 0.5 g/day to 3 g/day (41) | Purine antagonist (30) | Azathioprine intolerance (main) (37,41) | Salvage outcomes (31-41):  
- Overall improvement, 47%  
- Azathioprine intolerance, 58%  
- Refractory disease, 12%  
- Failure or side effects, 53%  
- Steroid withdrawal, 40%  
- Serious side effects, 3-33% |
|                          | Inhibits inosine monophosphate dehydrogenase (30) | Steroid-failure (less effective) (37,41) | Front-line outcomes (uncertain preference) (42):  
- Complete response, 88%  
- Partial response, 12%  
- Steroid withdrawal, 58%  
- Serious side effects, 3% |
|                          | Limits purine nucleotides (30) | Front-line therapy (uncertain preference) (42) |                        |
|                          | Impairs lymphocyte proliferation (30) | |                        |
| Budesonide, 3 mg three times/day combined with azathioprine (47) | Anti-inflammatory (46) | Front-line therapy (47) | After 6 months of therapy (47):  
- Laboratory normalization, 47%  
- Side effects, 28% |
|                          | High hepatic clearance (48) | No cirrhosis (53) |                        |
|                          | Inactive metabolites (48) | Mild disease (49) |                        |
|                          |                                  | Prednisone risk (49) |                        |

IL-2 interleukin-2; NF-κB nuclear factor kappa-B

![Figure 2](image)

Figure 2: Mechanisms of action of mycophenolate mofetil within lymphocytes. Mycophenolate mofetil is hydrolyzed to mycophenolic acid, which is a noncompetitive reversible inhibitor of inosine monophosphate dehydrogenase. The synthesis of purine-based nucleotides is impaired, the creation of new DNA is reduced and lymphocyte proliferation is inhibited. Inosine monophosphate is produced from ribose-5-phosphate (ribose-5P) and adenosine triphosphate (ATP)

A large randomized clinical trial involving 203 patients with these attributes subsequently demonstrated the advantages of budesonide over conventional prednisone-based treatment (47). Budesonide (3 mg three times/day) combined with azathioprine (1 mg/kg/day to 2 mg/kg/day) normalized serum aminotransferase levels more often (47% versus 18%) and with fewer side effects (28% versus 53%) than the standard regimen of prednisone (40 mg daily, tapered to 10 mg daily) combined with azathioprine (1 mg/kg/day to 2 mg/kg/day) when administered for six months (47). The frequency of histological resolution and the durability of the response remain unknown, and the low frequency of...
TABLE 2
Future feasible drug alternatives for autoimmune hepatitis (AIH)

<table>
<thead>
<tr>
<th>Feasible molecular intervention</th>
<th>Mechanisms of action (reference[s])</th>
<th>Precedents in human diseases (reference[s])</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nonmitogenic monoclonal antibodies to CD3 (anti-CD3)</strong></td>
<td>Targets T cell antigen receptor (17,55)</td>
<td>Type 1 diabetes (17,55)</td>
</tr>
<tr>
<td></td>
<td>Induces apoptosis of lymphocytes (17)</td>
<td>Few side effects (fever, rash, anemia, EBV infection) (17)</td>
</tr>
<tr>
<td></td>
<td>Releases TGF-β (17)</td>
<td>Hematological malignancies (17)</td>
</tr>
<tr>
<td></td>
<td>Induces regulatory T cells (17)</td>
<td>Rheumatoid arthritis, ITP (17)</td>
</tr>
<tr>
<td></td>
<td>Suppresses immune response (17)</td>
<td>AIH and cryoglobulinemia (17)</td>
</tr>
<tr>
<td><strong>Monoclonal antibodies to CD20 (anti-CD20)</strong></td>
<td>Targets CD20 expressed on B cells (17)</td>
<td>AIH and B cell lymphoma (17)</td>
</tr>
<tr>
<td></td>
<td>Depletes B lymphocytes (17)</td>
<td>Rare serious toxicities (progressive multifocal leukoencephalopathy) (17)</td>
</tr>
<tr>
<td></td>
<td>Impairs type 2 cytokine pathway (17)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Interferes with antibody-dependent cell-mediated cytotoxicities (17)</td>
<td></td>
</tr>
<tr>
<td><strong>Monoclonal antibodies to TNF-α (anti-TNF-α) or its receptor (etanercept)</strong></td>
<td>Interferes with type 1 cytokine pathway (15-17)</td>
<td>Crohn disease (16,17)</td>
</tr>
<tr>
<td></td>
<td>Impairs proliferation of cytotoxic T cells (15-17)</td>
<td>Rheumatoid arthritis (16,17)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Alcoholic hepatitis (ineffective) (16,17)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NAFLD (ineffective) (16,17)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Serious toxicities (infection, death, lung disease, SLE, AIH) (16,17)</td>
</tr>
<tr>
<td><strong>Recombinant cytotoxic T lymphocyte antigen 4 (anti-CD28) fused with immunoglobulin</strong></td>
<td>Resembles CD28 on lymphocyte (15-17)</td>
<td>Rheumatoid arthritis (15-17)</td>
</tr>
<tr>
<td></td>
<td>Binds B7 ligands on APC (15-17)</td>
<td>Mismatched bone marrow transplantation (15-17)</td>
</tr>
<tr>
<td></td>
<td>Interferes with second costimulatory signal of lymphocyte activation (15-17)</td>
<td>Multiple sclerosis (15-17)</td>
</tr>
<tr>
<td></td>
<td>Counters type 2 cytokine path (15-17)</td>
<td>Few side effects (infection) (16,17)</td>
</tr>
<tr>
<td><strong>Recombinant interleukin-10</strong></td>
<td>Reduces TNF-α (15-17)</td>
<td>Chronic hepatitis C (15-17)</td>
</tr>
<tr>
<td></td>
<td>Decreases inflammation (15-17)</td>
<td>Inflammatory bowel disease (15-17)</td>
</tr>
<tr>
<td></td>
<td>Impairs differentiation and proliferation of T lymphocytes (15-17)</td>
<td>Few dose-related side effects (anemia, thrombocytopenia, fever, chills, myalgias, headache) (16,17)</td>
</tr>
</tbody>
</table>

Numbers in parentheses indicate reference(s). APC Antigen presenting cell; EBV Epstein-Barr virus; ITP Idiopathic thrombocytopenic purpura; NAFLD Nonalcoholic fatty liver disease; SLE Systemic lupus erythematosus; TNF-α Tumour necrosis factor-alpha; TGF-β Transforming growth factor-beta

response (only 18%) and the high frequency of side effects (53%) in the patients treated with the standard regimen remain unexplained.

In combination with azathioprine, budesonide is emerging as an alternative front-line treatment for autoimmune hepatitis, but its off-label use must be cautious and conservative. There is still insufficient experience with this drug in treating the diverse presentations of autoimmune hepatitis to justify its blanket substitution for prednisone or prednisolone. Treatment appears to be best suited for treatment-naive, noncirrhotic and uncomplicated patients, and it has appeal as a first-line therapy in patients with asymptomatic, mild autoimmune hepatitis in whom the benefit-to-risk ratio of conventional prednisone treatment may be low. Patients with pre-existent osteopenia, hypertension, diabetes, obesity and emotional instability may be other candidates for the budesonide-azathioprine combination.

**FEASIBLE MOLECULAR INTERVENTIONS**

Site-specific molecular interventions are now feasible in autoimmune hepatitis primarily because of successes already achieved in other immune-mediated diseases (16,17) (Table 2). These interventions include the use of monoclonal antibodies and recombinant molecules that alter lymphocyte activation pathways, differentiation and proliferation. They constitute new treatment opportunities that are based on available technology and ongoing experiences in animal models and humans with autoimmune diseases. Other interventions, including synthetic peptides that block autoantigen display, oral tolerization against triggering antigens, T cell vaccination against cytotoxic T cell clones, adoptive transfer of regulatory T cells and silencing of genes that promote the autoimmune reaction, are feasible, but they are either untried, too preliminary, or inconsistently effective in animals or humans (16,17).

**Monoclonal antibodies**

Nonmitogenic monoclonal antibodies to CD3 target the T cell antigen receptor of liver-infiltrating cytotoxic T cells and induce apoptosis (55) (Table 2). This treatment has already been used successfully in animal models and humans with type 1 diabetes and awaits study in autoimmune hepatitis. Antibodies to CD20 can blunt clonal expansion of B cells and dampen antibody-mediated forms of cytotoxicity. Rituximab has already been used successfully in patients with rheumatoid arthritis (17). Monoclonal antibodies to tumour necrosis factor-alpha or its receptor are also feasible, but enthusiasm for this intervention has been dampened by the potential for serious toxicities (16,17). Anti-CD3 is the most promising intervention in this category because of its relevance to the pathogenic mechanisms of autoimmune hepatitis and its success in other immune-mediated human diseases (55).

**Recombinant molecules**

Recombinant cytotoxic T lymphocyte antigen 4 fused with immunoglobulin blocks the second costimulatory signal for immunocyte activation and can blunt the immune response (16,17,55) (Table 2). Abatacept is already approved in the United States and Europe for rheumatoid arthritis, and awaits study in autoimmune hepatitis. Recombinant IL-10 has anti-inflammatory effects that counterbalance the type 1 cytokine pathway and has been used in humans with chronic hepatitis C or inflammatory bowel disease (16). Recombinant IL-10 has had a satisfactory safety profile when administered in other human diseases and is a another candidate for study in autoimmune hepatitis (16). Cytotoxic T lymphocyte antigen-4 fused with immunoglobulin is the most promising intervention in this category because of its relevance to the pathogenic mechanisms of autoimmune hepatitis and its success in other immune-mediated human diseases (16).
THERAPEUTIC ANIMAL MODELS

The key to the emergence of new pharmacological and molecular therapies for autoimmune hepatitis is a therapeutic animal model of the human disease (18). Two promising mouse models have emerged while others are also being evaluated. One model is based on the immunization of female mice with plasmids of cytomegalovirus containing the antigenic region of the human cytochrome, CYP2D6, and human formiminotransferase cyclodeaminase (56). These are the antigenic targets of type 2 autoimmune hepatitis. The other model is based on the infection of mice with an adenosine virus expressing the antigenic region of human CYP2D6 (57). The infection model has the added advantages of recruiting inflammatory and immune cells to the damaged liver, generating a promiscuous immune response against self-antigens by molecular mimicry and developing extensive hepatic fibrosis. The major deficiencies in these current models are their short life-spans and, as a result, the inability to assess the long-term impact of treatment (18).

THERAPEUTIC DILEMMA

The new nonstandard drugs for autoimmune hepatitis create a treatment dilemma (58). Ideally, an international collaborative network of committed clinical investigators will be formed, funding resources will be available and large, rigorously designed clinical trials will be launched that fully define the value and role of these new agents. The quandary is whether to wait for more evidence or to treat with these new agents now. For autoimmune hepatitis and other uncommon diseases, expectations for clinical trials have been difficult to realize, and the promising new drugs warrant prudent, highly individualized and timely treatment decisions that are now applicable to clinical practice. Budesonide in combination with azathioprine can be considered as a front-line therapy, and it may be especially appropriate in treatment-naive patients with mild, early stage disease or with obesity, osteopenia, diabetes or hypertension that might be worsened by prednisone treatment. A calcineurin inhibitor (cyclosporine or tacrolimus) might be considered for refractory liver disease; mycophenolate mofetil appears to be best suited for patients with azathioprine intolerance.

The treatment dilemma in autoimmune hepatitis requires clinical judgment that is based on the immediacy of the clinical situation, failure of conventional treatment options, knowledge of the new agents and restriction of the new therapies to well-defined clinical situations that can be closely monitored. The societal need for fully evaluated new treatments stresses the need for a continuing effort to introduce new agents to standard clinical practice only after rigorous investigational scrutiny (58).

DISCLOSURES: Presented in part during the Canadian Digestive Diseases Week and annual winter meeting of the Canadian Association for the Study of the Liver, Montreal, Quebec, February 24, 2012. This review did not receive financial support from a funding agency or institution, and Albert J Czaja MD has no conflict of interests to declare.

REFERENCES

